跳至主要内容
临床试验/EUCTR2012-004031-23-BE
EUCTR2012-004031-23-BE进行中(未招募)不适用

Serum pharmacokinetics of Caspofungin in patients with liver failure.

Hopital Erasme0 个研究点开始时间: 2013年2月20日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • All successive patients with liver failure due to alcoholic hepatitis or decompensated cirrhosis admitted in the hospital will be included.
  • The inclusion criteria for patients with alcoholic hepatitis are
  • 1.age of 18 or older
  • 2.average alcohol intake of more than 50g per day during the 3 months before enrolment
  • 3.a Madrey’s discriminant function of 32 or more
  • 4.a liver biopsy consistent with alcoholic hepatitis (Mallory bodies surrounded by polymorphonuclear neutrophils)
  • The Child-Pugh score will determine the inclusion criteria for liver cirrhosis: patient will be included if the score is between 10 and 15 (score C)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 7
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 3

排除标准

  • -Patients with cachexia (Body mass index < 15kg/m²)
  • -Pregnant women

研究者

相似试验

Serum pharmacokinetics of Caspofungin in patients... | 临床试验